间充质干细胞对重症支气管哮喘治疗作用的研究进展

Research progress in therapeutic action of mesenchymal stem cell in severe bronchial asthma

支气管哮喘(哮喘)是一种常见的气道慢性疾病,糖皮质激素、β受体激动剂和白三烯受体拮抗剂单独或联合使用是目前该病的一线治疗策略。然而,即使给予了充分的治疗,仍有部分患儿的临床症状不受控制,最终形成重症哮喘。因此,寻找新的治疗措施迫在眉睫。间充质干细胞(MSCs)是一种具有多向分化潜能的干细胞,具有明显的抗炎、调节免疫作用,是哮喘潜在的治疗措施。该文重点讨论近年来MSCs在哮喘治疗方面的研究成果及进展。

Bronchial asthma is a common chronic airway disease. Single or combined use of glucocor-ticoid ,β-adrenoceptor agonist and leukotriene receptor antagonist are currently the first-line treatment of bron-chial asthma. However, even after comprehensive treatment, relevant clinical symptoms cannot be controlled and subsequently progress into severe bronchial asthma in certain affected children. Therefore, novel therapeu-tic interventions are to be urgently explored. Mesenchymal stem cells （MSCs） , as multi-potential stem cells, have been proven to play an important role in anti-inflammation and immune regulation. MSCs serve as a novel treatment of bronchial asthma. This article focuses on recent achievement and research progress of application of MSCs in the treatment of bronchial asthma.